Johanna Ihli, BSN
Former Registered Nurse (Emergency, Trauma, and Critical Care)
Independent Researcher in Drug-Induced Mitochondrial Dysfunction (DIMD)
ORCID: Johanna 0009-0008-1486-7242
How I Got Here
For over three decades, I lived and breathed medicine—first as a registered nurse in high-acuity settings like emergency, trauma, and critical care, then as a patient navigating a fragmented healthcare system while experiencing unexplained, progressive decline. I survived two separate exposures to fluoroquinolone antibiotics, nearly 20 years apart. What followed was not a single diagnosis, but a slow, multisystem progression of injuries and symptoms that standard evaluations couldn’t unify.
Key features included:
- Spontaneous tendon injuries and ruptures
- Muscle spasms, muscle contractures and widespread paresthesia
- Progressive neuropathy (including meralgia paresthetica)
- Autonomic instability
- Gait changes
- Unexplained rashes
- Visual impairment
- Insomnia
- Cognitive and psychological changes
- Profound, accumulating fatigue and exhaustion
I was examined by specialists across the country—Baylor College of Medicine, Vanderbilt, UT Knoxville, Our Lady of the Lake. Every single one, I told them about the tendon ruptures after Cipro. Not one connected the dots. Specialists ruled out issues in their domains, but the connection between fluoroquinolone exposure and mitochondrial dysfunction was never made. Treatments like NSAIDs and corticosteroids—now known to exacerbate mitochondrial issues—often led to further deterioration rather than recovery.
In 2025, comprehensive mitochondrial testing finally revealed a Complex I deficiency. This confirmed the long-suspected drug-induced mitochondrial dysfunction. It didn’t just explain my current state—it accounted for decades of delayed injury, partial compensation, eventual threshold crossing, and structural failure.
Why This Matters
Mitochondria are not abstract or rare—they are the energy powerhouses of every cell. They drive tissue repair, high-demand function, signaling, and overall resilience in the human body.
When mitochondrial function is impaired (e.g., by certain drugs), injury doesn’t always show up immediately. Cells compensate—sometimes for years or decades—until physiological thresholds are crossed. Only then do symptoms begin to appear—often affecting multiple body systems at the same time. Because the medication was stopped months or even years earlier, the connection between the drug and these symptoms is frequently overlooked. As a result, the condition is often misdiagnosed as chronic fatigue syndrome, lupus, dementia, or fibromyalgia.
Current clinical frameworks are geared toward acute, reversible toxicities. They struggle with delayed, cumulative, systemic patterns like this. Regulatory models (e.g., FDA toxicity guidelines) focus on time-limited, discrete reactions and often miss these longer-term mitochondrial effects.
This gap isn’t due to malice or neglect—it’s structural and educational. Modern medicine simply isn’t yet equipped to routinely recognize and address it.
My Background and Perspective
I approach this work with two complementary perspectives:
- Extensive clinical training as a registered nurse in emergency, trauma, and critical care, where I learned firsthand how guideline-based systems, diagnostic categories, and healthcare protocols function in real time.
- Personal experience as a patient enduring nearly two decades of progressive, unexplained multisystem decline following medication exposures.
This journey exposed the limitations of current frameworks—particularly when drug-related harm unfolds slowly, cumulatively, and outside standard timelines or classification boxes.
With objective confirmation of Complex I deficiency from 2025 mitochondrial testing, I now focus on bridging these gaps: strengthening recognition of delayed patterns so clinicians, regulators, and patients can intervene earlier and prevent similar trajectories.